Abstract
Research on dopamine (DA) and its receptors, and in particular the D2 receptor subclass, has been an intriguing and fast developing scientific field in the past 35 years. Methods of medicinal chemistry, molecular and structural biology as well as computational chemistry were used in the studies of DA receptors (DRs). Early attempts to describe DRs were based on a small amount of experimental data available and produced crude models at best. Once crystal structures of bacteriorhodopsin, rhodopsine, various G-protein coupled receptors, and finally D3 DR receptor became available, better and more detailed D2 DR receptor models emerged. These models gave us an insight into the mechanism of ligand-receptor interactions, and paved the way for the synthesis of new dopaminergic compounds, both agonists and antagonists and possible drugs for the treatment of different imbalances of the dopaminergic system. This review covers the key discoveries on the path to the creation of the D2 DR receptor model.
Keywords: 3D structure, computational chemistry, dopamine, GPCR, homology modeling, receptor.
Current Medicinal Chemistry
Title:Modeling of Dopamine D2 Receptor - Overview of 35-Year Evolution
Volume: 22 Issue: 25
Author(s): Vladimir Sukalovic, Vukic Soskic and Sladjana Kostic-Rajacic
Affiliation:
Keywords: 3D structure, computational chemistry, dopamine, GPCR, homology modeling, receptor.
Abstract: Research on dopamine (DA) and its receptors, and in particular the D2 receptor subclass, has been an intriguing and fast developing scientific field in the past 35 years. Methods of medicinal chemistry, molecular and structural biology as well as computational chemistry were used in the studies of DA receptors (DRs). Early attempts to describe DRs were based on a small amount of experimental data available and produced crude models at best. Once crystal structures of bacteriorhodopsin, rhodopsine, various G-protein coupled receptors, and finally D3 DR receptor became available, better and more detailed D2 DR receptor models emerged. These models gave us an insight into the mechanism of ligand-receptor interactions, and paved the way for the synthesis of new dopaminergic compounds, both agonists and antagonists and possible drugs for the treatment of different imbalances of the dopaminergic system. This review covers the key discoveries on the path to the creation of the D2 DR receptor model.
Export Options
About this article
Cite this article as:
Sukalovic Vladimir, Soskic Vukic and Kostic-Rajacic Sladjana, Modeling of Dopamine D2 Receptor - Overview of 35-Year Evolution, Current Medicinal Chemistry 2015; 22 (25) . https://dx.doi.org/10.2174/0929867322666150716114316
DOI https://dx.doi.org/10.2174/0929867322666150716114316 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhalational Anesthetics in Acute Severe Asthma
Current Drug Targets Progress in the Development of Selective Nitric Oxide Synthase (NOS) Inhibitors
Current Pharmaceutical Design Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Mechanisms of Drug Induced QT Interval Prolongation
Current Drug Safety Patent Selections:
Recent Patents on Signal Processing (Discontinued) Modulation of Immunity and the Inflammatory Response: A New Target for Treating Drug-resistant Epilepsy
Current Neuropharmacology CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design A Systematic Review of Current Progresses in the Nucleic Acid-Based Therapies for Neurodegeneration with Implications for Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme
Current Medicinal Chemistry ACE Inhibitor Delapril Prevents Ca<sup>2+</sup>-Dependent Blunting of I<sub>K1</sub> and Ventricular Arrhythmia in Ischemic Heart Disease
Current Molecular Medicine The Action of Prostaglandins on Ion Channels
Current Neuropharmacology Axonal Ionic Pathophysiology in Human Peripheral Neuropathy and Motor Neuron Disease
Current Neurovascular Research Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry Cytokines as Novel Therapeutic Agents for Neuroinflammatory Disorders: A Role for Interferon-β in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry - Central Nervous System Agents Synthesis of Novel and Highly Functionalized 4-hydroxycoumarin Chalcone and their Pyrazoline Derivatives as Anti-Tuberculosis Agents
Letters in Drug Design & Discovery Chemical Senses in Cancer Patients
Current Pharmaceutical Design Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics The Tortuous Road to an Ideal CGRP Function Blocker for the Treatment of Migraine
Current Topics in Medicinal Chemistry A Probable Topiramate-induced Limbs Paraesthesia and Rigid Fingers Flexion
Current Drug Safety